Drugs / SEA-TGT
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04254107 | May 2020 → Dec 2023 | cervical cancer, classic Hodgkin lymphoma, cutaneous melanoma, diffuse large B-cell lymphoma +8 | Seagen Inc. | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04585815 | Nov 2020 → May 2023 | non-small cell lung carcinoma | Pfizer | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SEA-TGT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04585815 ↗ |
| Route | Intravenous | “Given into the vein (IV; intravenously) on Day 1 of each 21-day cycle” NCT04254107 ↗ |